Home » Stocks » NBTX

Nanobiotix S.A. (NBTX)

Stock Price: $19.00 USD 0.25 (1.33%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
After-hours: $17.97 -1.03 (-5.42%) Jan 19, 4:05 PM
Market Cap 689.22M
Revenue (ttm) 76,000
Net Income (ttm) -53.46M
Shares Out 15.55M
EPS (ttm) -3.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $19.00
Previous Close $18.75
Change ($) 0.25
Change (%) 1.33%
Day's Open 19.73
Day's Range 19.00 - 20.63
Day's Volume 28,629
52-Week Range 15.95 - 20.63

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 4 days ago

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company”), a clinical-stage biotechnology company focused on developing ...

Business Wire - 1 week ago

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX (Paris:NANO) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company focused on developing first-in-clas...

Business Wire - 1 month ago

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – Nasdaq: NBTX – the ‘‘Company''), a clinical-stage nanomedicine company pioneering new appr...

Business Wire - 1 month ago

PARIS--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company''), a clinical-stage nanomedicine company pioneering new approaches to t...

Other stocks mentioned: NNBXF
Business Wire - 1 month ago

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company''), a clinical-stage nanomedicine company pioneering n...

Other stocks mentioned: NNBXF
Business Wire - 1 month ago

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company''), a clinical-stage nanomedicine company pioneering n...

Other stocks mentioned: NNBXF

About NBTX

Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated... [Read more...]

Industry
Biotechnology
IPO Date
Dec 11, 2020
CEO
Laurent Levy
Employees
98
Stock Exchange
NASDAQ
Ticker Symbol
NBTX
Full Company Profile

Financial Performance

In 2019, Nanobiotix's revenue was 2.54 million, a decrease of -26.96% compared to the previous year's 3.48 million. Losses were -50.92 million, 67.8% more than in 2018.

Financial numbers in millions EUR.
Financial Statements